PRELUDE THERAPEUTICS INC Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable
PRELUDE THERAPEUTICS INC (PRLD) had Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable of 10.69 million shares as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions · last filed 2026-08-11
- 2026-06-30: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 10.69M shares.
- 2026-03-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 10.10M shares.
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 9.53M shares.
- 2025-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 9.63M shares.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable |
|---|---|
| 2026-06-30 | 10.69M shares 10-Q · filed 2026-08-11 |
| 2026-03-31 | 10.10M shares 10-Q · filed 2026-05-12 |
| 2025-12-31 | 9.53M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 9.63M shares 10-Q · filed 2025-11-12 |
| 2025-06-30 | 9.53M shares 10-Q · filed 2025-08-14 |
| 2025-03-31 | 8.82M shares 10-Q · filed 2025-05-06 |
| 2024-12-31 | 8.52M shares 10-K · filed 2025-03-10 |
| 2024-09-30 | 8.15M shares 10-Q · filed 2024-11-06 |
| 2024-06-30 | 7.70M shares 10-Q · filed 2024-08-12 |
| 2024-03-31 | 7.00M shares 10-Q · filed 2024-05-07 |
| 2023-12-31 | 6.08M shares 10-K · filed 2024-02-15 |
| 2023-09-30 | 5.58M shares 10-Q · filed 2023-11-01 |
| 2023-06-30 | 4.94M shares 10-Q · filed 2023-08-03 |
| 2023-03-31 | 4.11M shares 10-Q · filed 2023-05-08 |
| 2022-12-31 | 3.59M shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 3.20M shares 10-Q · filed 2022-11-14 |
| 2022-06-30 | 2.74M shares 10-Q · filed 2022-08-09 |
| 2022-03-31 | 2.29M shares 10-Q · filed 2022-05-10 |
| 2021-12-31 | 2.06M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 2.09M shares 10-Q · filed 2021-11-12 |
| 2021-06-30 | 1.26M shares 10-Q · filed 2021-08-12 |
| 2021-03-31 | 1.21M shares 10-Q · filed 2021-05-11 |
| 2020-12-31 | 951.67K shares 10-K · filed 2021-03-16 |
| 2020-09-30 | 783.24K shares 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |